Developer docs
API playgroundTry for free, no card

Search company profiles

MimiVax

Full company profile

uuid0000nv8

Namestring
MimiVax
Legal namestring
MimiVax, Inc.
Websiteurl
mimivax.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

MimiVax is a privately held, clinical-stage biotechnology company founded in 2012 as a spin-off from Roswell Park Comprehensive Cancer Center in Buffalo, New York. The company develops immunotherapeutic vaccines and targeted therapies designed to control tumor growth and prevent recurrence, with its entire pipeline built on the licensed Roswell Park survivin-targeting platform. Its lead asset, SurVaxM, is a first-in-class, patented peptide mimic immunogen administered subcutaneously (with Montanide ISA 51 emulsion and sargramostim/GM-CSF) that stimulates both CD8+ T-cell and antibody-mediated anti-tumor responses against survivin, a cell-survival protein expressed in approximately 95% of glioblastomas and roughly 52% of neuroendocrine tumors. SurVaxM is being evaluated across multiple indications: newly diagnosed glioblastoma (Phase 2b SURVIVE, fully enrolled with positive interim), recurrent glioblastoma in combination with Merck's pembrolizumab, multiple myeloma with Celgene/BMS's lenalidomide, metastatic neuroendocrine tumors (Phase 2 launched May 2026), and pediatric high-grade gliomas.

MimiVax has no commercial product on the market. Revenue mechanics to date consist of a single $10M upfront payment from the November 2019 China-exclusive licensing agreement with Shanghai Fosun Pharmaceutical Industrial Development (which also carries up to $138M in development and sales milestones), plus cumulative equity and venture-philanthropy capital of approximately $25M from Buffalo Capital Partners, Varia Ventures, Fosun Pharma, the Brain Tumor Investment Fund / National Brain Tumor Society, the Sontag Foundation / Sontag Innovation Fund, MEDA Angels (part of Tech Coast Angels), the Roswell Park Alliance Foundation, and private investors. SurVaxM has been granted FDA Orphan Drug Designation (Aug 2017), Fast Track Designation for newly diagnosed glioblastoma (Oct 2023), and Supplemental Orphan Drug Designation for malignant gliomas (May 2024), providing 7 years of U.S. market exclusivity post-approval and Priority Review eligibility. The go-to-market model is a hybrid of geographic out-licensing (ex-U.S.), pharma partnership-sponsored combination trials (Merck, Celgene/BMS), and planned direct commercialization in retained territories once approved.

Short descriptiontext

MimiVax is a privately held, clinical-stage biotechnology company spun out of Roswell Park in 2012 developing SurVaxM, a first-in-class survivin-targeting peptide vaccine immunotherapy evaluated across glioblastoma, neuroendocrine tumors, multiple myeloma, and pediatric brain tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBuffalo, United States
HQ citystring
Buffalo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy vaccine, glioblastoma treatment, peptide mimic vaccine, survivin-targeting therapy, oncology biologics
Industry1 code
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biologics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Out-licensing upfront and milestone payments
TypeLicensing Royalties
Description

Geographic out-licensing of SurVaxM regional rights. China-exclusive license to Shanghai Fosun Pharmaceutical Industrial Development includes a $10 million USD upfront payment plus up to $28 million in development milestones and up to $110 million in sales milestones.

mimivax.com
2Private equity / venture capital / angel investment
TypeSubscription Recurring
Description

Pre-revenue clinical-stage biotech funded by approximately $25 million raised to date from venture philanthropy funds (Brain Tumor Investment Fund, Sontag Innovation Fund), venture capital (Varia Ventures), angel networks (MEDA Angels, Tech Coast Angels), pharma (Fosun Pharma), foundations (Roswell Park Alliance Foundation, American Cancer Society), and private investors. Funds directed at clinical development and registration.

mimivax.com
3Charitable donations and philanthropy
TypeTransaction Fee
Description

Donations to Roswell Park Alliance Foundation (e.g., through Empire State Ride, Ride for Roswell) provide critical seed funding for early-phase SurVaxM research and clinical studies.

mimivax.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
Pricing details1 tier
1Pre-commercial / quote-based partnership model
ModelOther
Notes

Pricing model not disclosed. Company is privately held and clinical-stage; SurVaxM is investigational and not yet commercially available. Investment and partnership opportunities are handled via direct contact.

mimivax.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MimiVax is a privately held, clinical-stage biotechnology company developing SurVaxM, a first-in-class peptide mimic immunotherapeutic vaccine that targets the survivin cell-survival protein expressed in approximately 95% of glioblastomas and many other cancers. The vaccine is delivered via subcutaneous injection with adjuvants to stimulate the patient's own T-cell and antibody-mediated immune response against survivin-expressing tumor cells. The company is evaluating SurVaxM across multiple cancer indications (newly diagnosed glioblastoma, recurrent glioblastoma, metastatic neuroendocrine tumors, multiple myeloma, and pediatric high-grade gliomas) and licenses regional commercialization rights to pharma partners such as Shanghai Fosun Pharmaceutical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 51% of nGBM patients receiving SurVaxM survived at least 2 years and 41% survived at least 3 years (Phase 2a)
+5 more records
Product overview1 text field

MimiVax offers a single-product clinical pipeline centered on its lead immunotherapeutic vaccine candidate SurVaxM, a first-in-class peptide mimic immunogen targeting the survivin cell-survival protein. Rather than a platform-plus-modules architecture, MimiVax's offering is a unified survivin-targeting immunotherapy platform in which the same SurVaxM candidate is being evaluated across multiple cancer indications (glioblastoma, multiple myeloma, neuroendocrine tumors, and pediatric brain tumors) and in combination with different standard-of-care agents such as temozolomide, REVLIMID (lenalidomide), and Keytruda (pembrolizumab). The company's broader portfolio consists of additional survivin-based immunotherapeutics (e.g., MV2C2 antibody program for myasthenia gravis) developed on technology licensed from Roswell Park Comprehensive Cancer Center. SurVaxM holds FDA Fast Track Designation for newly diagnosed glioblastoma and FDA Orphan Drug Designations for glioblastoma and malignant glioma, and is supported by a manufacturing partnership with UI Pharmaceuticals.

Product and service1 record
1SurVaxM
CategoryOncology Biologics / Cancer Immunotherapy
Description

SurVaxM is a first-in-class, patented peptide mimic immunotherapeutic vaccine that targets survivin, a cell-survival protein present in approximately 95% of glioblastomas and many other cancers. It is administered via subcutaneous injection with Montanide ISA 51 emulsion and sargramostim (GM-CSF) adjuvant and stimulates both CD8+ T-cell immunity and antibody-mediated anti-tumor responses. It is being evaluated in newly diagnosed glioblastoma (Phase 2b SURVIVE), recurrent glioblastoma (Phase 2 in combination with pembrolizumab), metastatic neuroendocrine tumors (Phase 2), multiple myeloma (Phase 1 in combination with lenalidomide/REVLIMID), and pediatric relapsed/recurrent high-grade gliomas (Phase 1). SurVaxM is intended for oncology indications with limited treatment options, including both hematologic and solid tumors.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCore — Clinical And Commercial Manufacturing PartnerTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-10
Description

Contract drug product development and manufacturing organization (CDMO) that successfully completed clinical manufacture of SurVaxM at its newly qualified $26M sterile manufacturing facility. SurVaxM is the first drug product produced in UIP's new facility; UIP will support larger clinical and commercial lots. Over 50 years of CDMO experience.

Strategic tierFlagship — Largest Single Financing Event And Primary Ex-U.S. Commercialization RouteTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-11-18
Description

China-exclusive licensing agreement for SurVaxM to clinically develop and commercialize the therapy in specified territories in China. MimiVax received a $10 million USD upfront payment and is eligible for up to $28 million in development milestones and up to $110 million in sales milestones. Fosun Pharma handles clinical, regulatory, and commercial pathways for China. Fosun Pharma is a leading Chinese healthcare group listed on Shanghai and Hong Kong stock exchanges.

Strategic tierFlagship — Founding Institution And Primary Clinical Research PartnerTypeStrategic or Co-development Partner
Description

Founding partner from which MimiVax was spun off in 2012. Roswell Park originated the SurVaxM technology, hosts central trial sites, conducts Phase 1/2 NET and pediatric trials, and provides ongoing clinical collaboration. Co-investigator institution with Dr. Robert Fenstermaker (Chair Emeritus of Neurosurgery, co-founder) and Dr. Michael Ciesielski (CEO and co-founder).

Strategic tierMinor — Combination-Therapy Partner For Multiple Myeloma IndicationTypeStrategic or Co-development Partner
Description

Roswell Park partnered with Celgene Corp. (manufacturer of REVLIMID/lenalidomide) on Phase 1 clinical trial of SurVaxM in combination with REVLIMID for multiple myeloma. Multiple myeloma trial fully enrolled.

Strategic tierMinor — Combination-Therapy Partner For Recurrent Gbm IndicationTypeStrategic or Co-development Partner
Description

Partnered with Merck for evaluation of SurVaxM in combination with pembrolizumab (Keytruda) for recurrent glioblastoma; trial fully enrolled.

Strategic tierCore — Multi-Center Clinical Trial Lead Pi SiteTypeStrategic or Co-development Partner
Description

Phase 2a and Phase 2b SURVIVE trial site under PI Dr. Manmeet Ahluwalia, MD, MBA (Fernandez Family Foundation Endowed Chair in Cancer Research; Chief of Medical Oncology, Deputy Director and Chief Scientific Officer at Miami Cancer Institute).

Strategic tierCore — Multi-Center Clinical Trial SiteTypeStrategic or Co-development Partner
Description

Phase 2a trial site for SurVaxM in newly diagnosed glioblastoma; Phase 2b SURVIVE trial site. Contributes to clinical evidence base.

Strategic tierCore — Multi-Center Clinical Trial SiteTypeStrategic or Co-development Partner
Description

Phase 2a trial site for SurVaxM in nGBM; Phase 2b SURVIVE trial site. Co-author institution on Phase 2a manuscript.

Strategic tierCore — Multi-Center Clinical Trial SiteTypeStrategic or Co-development Partner
Description

Phase 2a trial site for SurVaxM in newly diagnosed glioblastoma; co-author institution on Phase 2a manuscript.

Strategic tierMinor — Phase 2A Trial SiteTypeStrategic or Co-development Partner
Description

Phase 2a trial site for SurVaxM in newly diagnosed glioblastoma.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage developer of DCVax-L, a dendritic cell-based therapeutic vaccine for glioblastoma. Direct competitor in the GBM immunotherapy space and the most analogous single-indication therapeutic cancer vaccine company in oncology.

2Istari Oncology
TypeDirect peer
Description

Clinical-stage biotech developing PVSRIPO, a polio virus-based immunotherapy for recurrent glioblastoma. Closely comparable in target indication (GBM) and clinical-stage development profile to MimiVax.

TypeBroad incumbent
Description

Commercial-stage oncology company with Optune/TTFields, an FDA-approved therapy for newly diagnosed and recurrent glioblastoma. Operates in the same patient population as MimiVax and represents the standard-of-care alternative in GBM.

TypeBroad incumbent
Description

Commercial-stage biotech with an mRNA-based personalized cancer vaccine program (mRNA-4157/V940, partnered with Merck) and a broader oncology pipeline. Comparable as a leading therapeutic cancer vaccine developer with significantly greater resources and platform breadth.

TypeBroad incumbent
Description

Commercial-stage biotech (BNT122/BNT121, FixVac) developing mRNA-based and neoantigen-based therapeutic cancer vaccines. Comparable in therapeutic cancer vaccine modality and multi-indication platform strategy, though at significantly greater scale.

TypeDirect peer
Description

Clinical-stage developer of neoantigen-based therapeutic cancer vaccines (SLATE, GRANITE) in oncology. Directly comparable as a single-platform therapeutic cancer vaccine company with multiple indication programs.

TypeDirect peer
Description

Clinical-stage Norwegian biotech developing the Vaccibody DNA-based therapeutic vaccine platform, with lead oncology programs in HPV-driven cancers. Comparable as a therapeutic cancer vaccine developer with a modular platform.

TypeDirect peer
Description

Clinical-stage developer of personalized neoantigen cancer vaccines (using cNeT and PELEUS platforms) for non-small cell lung cancer and melanoma. Comparable as a clinical-stage therapeutic cancer vaccine company targeting tumor-specific antigens.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing PROSTVAC and other therapeutic cancer vaccines, plus immune checkpoint antibodies. Comparable in therapeutic cancer vaccine focus and combination-immunotherapy strategy.

TypeBroad incumbent
Description

Large pharma partner of MimiVax in the recurrent GBM trial evaluating SurVaxM in combination with pembrolizumab (Keytruda). Operates broadly in oncology and is a potential acquirer or strategic partner for the company.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MimiVax

Oncology Biologicsmimivax.com

MimiVax is a privately held, clinical-stage biotechnology company spun out of Roswell Park in 2012 developing SurVaxM, a first-in-class survivin-targeting peptide vaccine immunotherapy evaluated across glioblastoma, neuroendocrine tumors, multiple myeloma, and pediatric brain tumors.

What MimiVax does

MimiVax is a privately held, clinical-stage biotechnology company founded in 2012 as a spin-off from Roswell Park Comprehensive Cancer Center in Buffalo, New York. The company develops immunotherapeutic vaccines and targeted therapies designed to control tumor growth and prevent recurrence, with its entire pipeline built on the licensed Roswell Park survivin-targeting platform. Its lead asset, SurVaxM, is a first-in-class, patented peptide mimic immunogen administered subcutaneously (with Montanide ISA 51 emulsion and sargramostim/GM-CSF) that stimulates both CD8+ T-cell and antibody-mediated anti-tumor responses against survivin, a cell-survival protein expressed in approximately 95% of glioblastomas and roughly 52% of neuroendocrine tumors. SurVaxM is being evaluated across multiple indications: newly diagnosed glioblastoma (Phase 2b SURVIVE, fully enrolled with positive interim), recurrent glioblastoma in combination with Merck's pembrolizumab, multiple myeloma with Celgene/BMS's lenalidomide, metastatic neuroendocrine tumors (Phase 2 launched May 2026), and pediatric high-grade gliomas.

MimiVax has no commercial product on the market. Revenue mechanics to date consist of a single $10M upfront payment from the November 2019 China-exclusive licensing agreement with Shanghai Fosun Pharmaceutical Industrial Development (which also carries up to $138M in development and sales milestones), plus cumulative equity and venture-philanthropy capital of approximately $25M from Buffalo Capital Partners, Varia Ventures, Fosun Pharma, the Brain Tumor Investment Fund / National Brain Tumor Society, the Sontag Foundation / Sontag Innovation Fund, MEDA Angels (part of Tech Coast Angels), the Roswell Park Alliance Foundation, and private investors. SurVaxM has been granted FDA Orphan Drug Designation (Aug 2017), Fast Track Designation for newly diagnosed glioblastoma (Oct 2023), and Supplemental Orphan Drug Designation for malignant gliomas (May 2024), providing 7 years of U.S. market exclusivity post-approval and Priority Review eligibility. The go-to-market model is a hybrid of geographic out-licensing (ex-U.S.), pharma partnership-sponsored combination trials (Merck, Celgene/BMS), and planned direct commercialization in retained territories once approved.

MimiVax firmographics

Firmographics
Name
MimiVax
Legal name
MimiVax, Inc.
Website
https://mimivax.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
MimiVax is a privately held, clinical-stage biotechnology company spun out of Roswell Park in 2012 developing SurVaxM, a first-in-class survivin-targeting peptide vaccine immunotherapy evaluated across glioblastoma, neuroendocrine tumors, multiple myeloma, and pediatric brain tumors.
Ownership category
akta.pro rank

MimiVax industry classification

Industry
Product category
Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cancer immunotherapy vaccine
  • Glioblastoma treatment
  • Peptide mimic vaccine
  • Survivin-targeting therapy
  • Oncology biologics

Where MimiVax is headquartered

Location

Headquarters

HQ city
Buffalo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MimiVax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

  1. Out-licensing upfront and milestone payments: Geographic out-licensing of SurVaxM regional rights. China-exclusive license to Shanghai Fosun Pharmaceutical Industrial Development includes a $10 million USD upfront payment plus up to $28 million in development milestones and up to $110 million in sales milestones.
  2. Private equity / venture capital / angel investment: Pre-revenue clinical-stage biotech funded by approximately $25 million raised to date from venture philanthropy funds (Brain Tumor Investment Fund, Sontag Innovation Fund), venture capital (Varia Ventures), angel networks (MEDA Angels, Tech Coast Angels), pharma (Fosun Pharma), foundations (Roswell Park Alliance Foundation, American Cancer Society), and private investors. Funds directed at clinical development and registration.
  3. Charitable donations and philanthropy: Donations to Roswell Park Alliance Foundation (e.g., through Empire State Ride, Ride for Roswell) provide critical seed funding for early-phase SurVaxM research and clinical studies.

Pricing tiers

ModelBillingPrice
Other—Pre-commercial / quote-based partnership model

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

MimiVax product offering

Product offering

Core offering

MimiVax is a privately held, clinical-stage biotechnology company developing SurVaxM, a first-in-class peptide mimic immunotherapeutic vaccine that targets the survivin cell-survival protein expressed in approximately 95% of glioblastomas and many other cancers. The vaccine is delivered via subcutaneous injection with adjuvants to stimulate the patient's own T-cell and antibody-mediated immune response against survivin-expressing tumor cells. The company is evaluating SurVaxM across multiple cancer indications (newly diagnosed glioblastoma, recurrent glioblastoma, metastatic neuroendocrine tumors, multiple myeloma, and pediatric high-grade gliomas) and licenses regional commercialization rights to pharma partners such as Shanghai Fosun Pharmaceutical.

Product overview

MimiVax offers a single-product clinical pipeline centered on its lead immunotherapeutic vaccine candidate SurVaxM, a first-in-class peptide mimic immunogen targeting the survivin cell-survival protein. Rather than a platform-plus-modules architecture, MimiVax's offering is a unified survivin-targeting immunotherapy platform in which the same SurVaxM candidate is being evaluated across multiple cancer indications (glioblastoma, multiple myeloma, neuroendocrine tumors, and pediatric brain tumors) and in combination with different standard-of-care agents such as temozolomide, REVLIMID (lenalidomide), and Keytruda (pembrolizumab). The company's broader portfolio consists of additional survivin-based immunotherapeutics (e.g., MV2C2 antibody program for myasthenia gravis) developed on technology licensed from Roswell Park Comprehensive Cancer Center. SurVaxM holds FDA Fast Track Designation for newly diagnosed glioblastoma and FDA Orphan Drug Designations for glioblastoma and malignant glioma, and is supported by a manufacturing partnership with UI Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • SurVaxM SurVaxM is a first-in-class, patented peptide mimic immunotherapeutic vaccine that targets survivin, a cell-survival protein present in approximately 95% of glioblastomas and many other cancers. It is administered via subcutaneous injection with Montanide ISA 51 emulsion and sargramostim (GM-CSF) adjuvant and stimulates both CD8+ T-cell immunity and antibody-mediated anti-tumor responses. It is being evaluated in newly diagnosed glioblastoma (Phase 2b SURVIVE), recurrent glioblastoma (Phase 2 in combination with pembrolizumab), metastatic neuroendocrine tumors (Phase 2), multiple myeloma (Phase 1 in combination with lenalidomide/REVLIMID), and pediatric relapsed/recurrent high-grade gliomas (Phase 1). SurVaxM is intended for oncology indications with limited treatment options, including both hematologic and solid tumors.

Quantifiable outcome

  • 51% of nGBM patients receiving SurVaxM survived at least 2 years and 41% survived at least 3 years (Phase 2a)
  • +5 more outcomes

Companies that use MimiVax

Customer profile

Named customers13 records

Segments5 records

Ideal customer profiles3 records

MimiVax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MimiVax partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core — clinical and commercial manufacturing partner, flagship — largest single financing event and primary ex-u.s. commercialization route, flagship — founding institution and primary clinical research partner, minor — combination-therapy partner for multiple myeloma indication, minor — combination-therapy partner for recurrent gbm indication, core — multi-center clinical trial lead pi site, core — multi-center clinical trial site and minor — phase 2a trial site.

  • UI Pharmaceuticals (University of Iowa College of Pharmacy)core — clinical and commercial manufacturing partnerImplementation/ SI/ Consulting Partner · 10 January 2025Contract drug product development and manufacturing organization (CDMO) that successfully completed clinical manufacture of SurVaxM at its newly qualified $26M sterile manufacturing facility. SurVaxM is the first drug product produced in UIP's new facility; UIP will support larger clinical and commercial lots. Over 50 years of CDMO experience.
  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma)flagship — largest single financing event and primary ex-u.s. commercialization routeOEM/ Whitelabel/ Licensing Partner · 18 November 2019China-exclusive licensing agreement for SurVaxM to clinically develop and commercialize the therapy in specified territories in China. MimiVax received a $10 million USD upfront payment and is eligible for up to $28 million in development milestones and up to $110 million in sales milestones. Fosun Pharma handles clinical, regulatory, and commercial pathways for China. Fosun Pharma is a leading Chinese healthcare group listed on Shanghai and Hong Kong stock exchanges.
  • Roswell Park Comprehensive Cancer Centerflagship — founding institution and primary clinical research partnerStrategic or Co-development PartnerFounding partner from which MimiVax was spun off in 2012. Roswell Park originated the SurVaxM technology, hosts central trial sites, conducts Phase 1/2 NET and pediatric trials, and provides ongoing clinical collaboration. Co-investigator institution with Dr. Robert Fenstermaker (Chair Emeritus of Neurosurgery, co-founder) and Dr. Michael Ciesielski (CEO and co-founder).
  • Celgene Corp. (Bristol Myers Squibb)minor — combination-therapy partner for multiple myeloma indicationStrategic or Co-development PartnerRoswell Park partnered with Celgene Corp. (manufacturer of REVLIMID/lenalidomide) on Phase 1 clinical trial of SurVaxM in combination with REVLIMID for multiple myeloma. Multiple myeloma trial fully enrolled.
  • Merck (Keytruda)minor — combination-therapy partner for recurrent gbm indicationStrategic or Co-development PartnerPartnered with Merck for evaluation of SurVaxM in combination with pembrolizumab (Keytruda) for recurrent glioblastoma; trial fully enrolled.
  • Miami Cancer Institute (Baptist Health South Florida)core — multi-center clinical trial lead pi siteStrategic or Co-development PartnerPhase 2a and Phase 2b SURVIVE trial site under PI Dr. Manmeet Ahluwalia, MD, MBA (Fernandez Family Foundation Endowed Chair in Cancer Research; Chief of Medical Oncology, Deputy Director and Chief Scientific Officer at Miami Cancer Institute).
  • Cleveland Cliniccore — multi-center clinical trial siteStrategic or Co-development PartnerPhase 2a trial site for SurVaxM in newly diagnosed glioblastoma; Phase 2b SURVIVE trial site. Contributes to clinical evidence base.
  • Dana-Farber Cancer Institutecore — multi-center clinical trial siteStrategic or Co-development PartnerPhase 2a trial site for SurVaxM in nGBM; Phase 2b SURVIVE trial site. Co-author institution on Phase 2a manuscript.
  • Massachusetts General Hospitalcore — multi-center clinical trial siteStrategic or Co-development PartnerPhase 2a trial site for SurVaxM in newly diagnosed glioblastoma; co-author institution on Phase 2a manuscript.
  • Beth Israel Deaconess Medical Centerminor — phase 2a trial siteStrategic or Co-development PartnerPhase 2a trial site for SurVaxM in newly diagnosed glioblastoma.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

MimiVax competitors and assessment

Company assessment

Direct peers

  • Northwest Biotherapeutics: Clinical-stage developer of DCVax-L, a dendritic cell-based therapeutic vaccine for glioblastoma. Direct competitor in the GBM immunotherapy space and the most analogous single-indication therapeutic cancer vaccine company in oncology.
  • Istari Oncology: Clinical-stage biotech developing PVSRIPO, a polio virus-based immunotherapy for recurrent glioblastoma. Closely comparable in target indication (GBM) and clinical-stage development profile to MimiVax.
  • Gritstone bio: Clinical-stage developer of neoantigen-based therapeutic cancer vaccines (SLATE, GRANITE) in oncology. Directly comparable as a single-platform therapeutic cancer vaccine company with multiple indication programs.
  • Nykode Therapeutics: Clinical-stage Norwegian biotech developing the Vaccibody DNA-based therapeutic vaccine platform, with lead oncology programs in HPV-driven cancers. Comparable as a therapeutic cancer vaccine developer with a modular platform.
  • Achilles Therapeutics: Clinical-stage developer of personalized neoantigen cancer vaccines (using cNeT and PELEUS platforms) for non-small cell lung cancer and melanoma. Comparable as a clinical-stage therapeutic cancer vaccine company targeting tumor-specific antigens.
  • Agenus: Clinical-stage immuno-oncology company developing PROSTVAC and other therapeutic cancer vaccines, plus immune checkpoint antibodies. Comparable in therapeutic cancer vaccine focus and combination-immunotherapy strategy.

Broad incumbents

  • Novocure: Commercial-stage oncology company with Optune/TTFields, an FDA-approved therapy for newly diagnosed and recurrent glioblastoma. Operates in the same patient population as MimiVax and represents the standard-of-care alternative in GBM.
  • Moderna: Commercial-stage biotech with an mRNA-based personalized cancer vaccine program (mRNA-4157/V940, partnered with Merck) and a broader oncology pipeline. Comparable as a leading therapeutic cancer vaccine developer with significantly greater resources and platform breadth.
  • BioNTech: Commercial-stage biotech (BNT122/BNT121, FixVac) developing mRNA-based and neoantigen-based therapeutic cancer vaccines. Comparable in therapeutic cancer vaccine modality and multi-indication platform strategy, though at significantly greater scale.
  • Merck: Large pharma partner of MimiVax in the recurrent GBM trial evaluating SurVaxM in combination with pembrolizumab (Keytruda). Operates broadly in oncology and is a potential acquirer or strategic partner for the company.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

MimiVax social profiles

Digital presence

MimiVax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MimiVax leadership team

Management profile

Number of profiles

Profiles3 records

MimiVax funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MimiVax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MimiVax

What does MimiVax do?

MimiVax is a privately held, clinical-stage biotechnology company developing SurVaxM, a first-in-class peptide mimic immunotherapeutic vaccine that targets the survivin cell-survival protein expressed in approximately 95% of glioblastomas and many other cancers. The vaccine is delivered via subcutaneous injection with adjuvants to stimulate the patient's own T-cell and antibody-mediated immune response against survivin-expressing tumor cells. The company is evaluating SurVaxM across multiple cancer indications (newly diagnosed glioblastoma, recurrent glioblastoma, metastatic neuroendocrine tumors, multiple myeloma, and pediatric high-grade gliomas) and licenses regional commercialization rights to pharma partners such as Shanghai Fosun Pharmaceutical.

Is MimiVax a public or private company?

MimiVax is a private company. It is classified as venture growth investor backed and is currently operating.

When was MimiVax founded?

MimiVax was founded in 2012. It employs 1 to 10 people.

Where is MimiVax based?

MimiVax is headquartered in Buffalo, United States, in the North America region.

How does MimiVax make money?

Three revenue lines are on record. Out-licensing upfront and milestone payments are the primary driver. The others are private equity / venture capital / angel investment and charitable donations and philanthropy.

Who are MimiVax's main competitors?

Direct peers on record are Northwest Biotherapeutics, Istari Oncology, Gritstone bio, Nykode Therapeutics, Achilles Therapeutics and Agenus. Broad incumbents are Novocure, Moderna, BioNTech and Merck.

Does MimiVax have an API?

No public API is recorded for MimiVax.

What industry is MimiVax in?

MimiVax's product category is Oncology Biologics. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterMimiVax looks to younger patients after SurVaxM trial missMimiVax plans to discuss expedited regulatory pathways for its SurVaxM vaccine after a Phase IIb glioblastoma trial missed its primary endpoint. Across 233 patients, median overall survival was 22.8 months with SurVaxM versus 20.3 months with placebo, a difference not statistically significant (p=0.076). The company noted better outcomes in a prespecified group of younger patients.FierceBiotechMimiVax’s cancer vaccine fails phase 2 glioblastoma study, but CEO still sees data as ‘inspiring’MimiVax's SurVaxM vaccine failed its phase 2 glioblastoma trial's primary endpoint, but showed a median overall survival benefit of 24.2 months versus 20.2 months in patients under 65. The company plans to pursue FDA approval based on these subgroup results.Roswell Park Comprehensive Cancer CenterMimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsBiotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center have launched a Phase 2 clinical trial evaluating SurVaxM, a peptide vaccine targeting the survivin protein, in combination with temozolomide for patients with progressing metastatic neuroendocrine tumors (NETs). The trial, conducted at Roswell Park in Buffalo, New York, follows Phase 1 findings demonstrating that SurVaxM was well tolerated and showed measurable clinical benefit with elevated antibody responses in NET patients. SurVaxM is also being evaluated in glioblastoma and pediatric brain tumors as MimiVax advances its survivin-targeting platform across multiple cancer indications.PharmaTimesMimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumoursA new phase 2 clinical trial has opened at Roswell Park Comprehensive Cancer Center to evaluate the cancer vaccine SurVaxM combined with temozolomide for patients with progressing metastatic neuroendocrine tumours, sponsored jointly by MimiVax and Roswell Park. The trial will compare the combination therapy against temozolomide alone in patients whose disease continues to advance after first-line treatment, with earlier phase 1 findings showing the vaccine was well tolerated and produced measurable clinical benefit. This follows MimiVax's completion of data collection for its phase 2b SURVIVE trial in newly diagnosed glioblastoma and assessment in paediatric brain tumours and multiple myeloma.Roswell Park Comprehensive Cancer CenterMimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsMimiVax Inc. and Roswell Park Comprehensive Cancer Center have jointly launched a phase 2 clinical trial to evaluate the immunotherapy SurVaxM in combination with temozolomide for patients with metastatic neuroendocrine tumors. This development builds on positive phase 1 findings regarding safety and immune response, aiming to address limited treatment options for this rare cancer. The trial is being conducted at Roswell Park in Buffalo, New York, under the direction of principal investigator Dr. Jasmeet Kaur.InsideprecisionmedicineMolecular Biomarker May Identify Glioblastoma Candidates for SurVaxM TherapyResearchers from Roswell Park Comprehensive Cancer Center identified a five-gene molecular signature that predicts improved survival in glioblastoma patients treated with the SurVaxM vaccine. The study, led by co-developer Michael Ciesielski, found that long-term survivors exhibited high expression of specific genes and greater immunological activity compared to short-term survivors. MimiVax, the spin-out company producing SurVaxM, is now focusing on completing Phase IIb trials to advance the therapy toward commercialization.Roswell Park Comprehensive Cancer CenterRoswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxMRoswell Park Comprehensive Cancer Center announced that its phase 2B SURVIVE clinical trial for the immunotherapy SurVaxM in glioblastoma patients will continue following an interim analysis that met prespecified standards. The trial, sponsored by MimiVax Inc., is currently underway at 11 U.S. sites and aims to evaluate the safety and survival benefit of combining SurVaxM with standard-of-care treatments.PR NewswireMimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma TreatmentMimiVax, Inc. and UI Pharmaceuticals have successfully manufactured SurVaxM, a novel immunotherapeutic vaccine targeting glioblastoma, at UIP's newly qualified $26 million sterile manufacturing facility in Iowa — the first drug product produced at this site. The vaccine is currently being evaluated in a randomized Phase 2b clinical trial at 11 leading cancer centers across the United States and has received FDA fast track designation for newly diagnosed glioblastoma. Both companies view this milestone as advancing their path toward transformative cancer therapies and improved patient outcomes.NatureDeveloping a new cancer immunotherapy, SurVaxM from bench to bedsideMimiVax, Inc. is developing SurVaxM, an immunotherapy targeting the survivin protein for glioblastoma, with its SURVIVE phase 2b trial currently ongoing at 11 US cancer centers. The company has also secured an exclusive licensing agreement with Fosun Pharma for the distribution of SurVaxM in China upon regulatory approval.WKBW 7 News Buffalo'It touches all of us': Breast cancer survivor bikes across New York a ninth time raising money for researchDanielle Casucci is undertaking her ninth Empire State Ride to raise funds for cancer research at Roswell Park, where she previously received treatment. The proceeds support clinical trials for MimiVax's brain cancer vaccine, which was developed at Roswell Park and is currently in the trial phase under Casucci's management as Vice President of Clinical Operations.